软件引导MRI-经直肠超声融合前列腺活检平台中自由手与固定臂空间跟踪方法的系统综述与Meta分析
该系统综述与Meta分析比较了软件引导MRI-经直肠超声融合前列腺活检中自由手与固定臂两种空间跟踪方法的癌症检出率。纳入前瞻性试验和队列研究的原始分析,使用PI-RADS v2.0及以上版本并针对PI-RADS 3分及以上病灶。结果显示两种方法总体前列腺癌检出率和临床显著前列腺癌检出率无显著差异,仅在每病灶取2针的亚组中固定臂平台略有优势。
要点
- 自由手与固定臂平台总体前列腺癌检出率分别为0.674和0.681,无显著差异(P = .88)。
- 临床显著前列腺癌检出率分别为0.492和0.500,无显著差异(P = .90)。
- 仅在每病灶取2针的亚组中,固定臂平台检出率显著优于自由手平台(P < .001)。
核心结论
- 固定臂平台在癌症检出方面与自由手平台表现相似,但在取样更少时显示出轻微优势。
- 虽然跟踪方法差异似乎细微,但需要对平台特定特征的临床影响进行进一步研究。
研究设计与样本
- 系统综述与Meta分析,纳入前瞻性试验和队列研究的已发表原始分析,入组活检初治患者接受软件引导MRI-经直肠超声融合前列腺活检。
- 纳入标准包括使用前列腺影像报告和数据系统(PI-RADS)v2.0或更高版本,并针对PI-RADS 3分或更高分级的病灶。
- 采用随机效应模型评估两种平台的总前列腺癌检出率和临床显著前列腺癌检出率,临床显著前列腺癌尽可能标准化为Gleason分级分组2级或更高。
- 按每病灶平均穿刺针数进行亚组分析。
主要发现
- 自由手系统前列腺癌检出率为0.674,固定臂系统为0.681。
- 自由手系统临床显著前列腺癌检出率为0.492,固定臂系统为0.500。
- 自由手与固定臂平台在总体前列腺癌(P = .88)和临床显著前列腺癌(P = .90)检出率上均无显著差异。
- 亚组分析显示,仅在每病灶取2针时,自由手与固定臂平台间前列腺癌检出率和临床显著前列腺癌检出率存在显著差异(P < .001),有利于固定臂平台。
局限性
- 原文结论指出需要对平台特定特征的临床影响进行进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cancer detection rate (CDR) between the 2 dominant spatial tracking methodologies in software-guided MRI-transrectal ultrasound fusion prostate biopsy (SGF-Bx) platforms: fixed-arm and free-hand. METHODS: We conducted a systematic review and meta-analysis on published primary analyses of prospective trials and cohort studies that enrolled biopsy-naïve patients for SFG-Bx. Inclusion criteria included the use of the Prostate Imaging Reporting & Data System (PI-RADS) v2.0 or later and the targeting of lesions graded as PI-RADS 3 or higher. Random effects models were used to assess the overall prostate cancer (PCa) CDR and the clinically significant prostate cancer (csPCa) CDR for both platforms. csPCa was standardized to a definition of Gleason Grade Group 2 or higher when possible. Subgroup analysis was performed by stratifying studies into the average number of cores taken per lesion. RESULTS: The PCa CDR was 0.674 for free-hand systems and 0.681 for fixed-arm systems. The csPCa CDR was 0.492 for free-hand systems and 0.500 for fixed-hand systems. There was no significant difference between free-hand and fixed-arm cancer detection rates for both overall PCa (P = .88) and csPCa (P = .90). Subgroup analyses revealed significant PCa CDR and csPCa CDR differences (P < .001) between free-hand and fixed-arm platforms only when 2 cores per lesion were taken, in favor of fixed-arm platforms. CONCLUSIONS: Fixed-arm platforms performed similarly in cancer detection to free-hand platforms but show a minor benefit on fewer samples. While tracking methodology differences appear subtle, further investigation into the clinical impact of platform-specific features are warranted.
引用
- Zhao CC, Rossi JK, Wysock JS, et al. Systematic Review and Meta-Analysis of Free-Hand and Fixed-Arm Spatial Tracking Methodologies in Software-Guided MRI-TRUS Fusion Prostate Biopsy Platforms. Urology. 2022. PMID: 36243143. doi:10.1016/j.urology.2022.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。